The potential of combi-molecules with DNA-damaging function as anticancer agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• DNA-damaging agents (e.g., methylating, chloroethylating, platinum-based) are vital anticancer drugs.
• Clinical use is limited by side effects, toxicity, poor selectivity, and resistance.
• Novel strategies are needed to enhance the therapeutic index of DNA-damaging agents.

Purpose of the Study:

• To review the development of combi-molecules for enhanced anticancer therapy.
• To highlight combi-molecules with improved DNA-damaging potency and tumor selectivity.
• To discuss future opportunities and challenges in combi-molecule discovery.

Main Methods:

• Literature review focusing on combi-molecule design and preclinical/clinical data.
• Analysis of strategies combining DNA-damaging agents with bioactive molecules or carriers.
• Evaluation of studies demonstrating in vitro and in vivo anticancer activity.

Main Results:

• Combi-molecules simultaneously target multiple pathways, potentially increasing potency.
• Studies show enhanced anticancer activity, efficacy, and tumor selectivity of combi-molecules.
• Combi-molecules demonstrate reduced side reactions compared to parent compounds.

Conclusions:

• Combi-molecules represent a promising approach to overcome limitations of traditional DNA-damaging anticancer drugs.
• Further research into combi-molecule design can lead to more effective and safer cancer therapies.
• Addressing challenges in discovery and development is crucial for clinical translation.